RUNX1 was studied for its role in NAFLD, because it has been proposed as a regulator of angiogenesis (via vascular endothelial growth factor (VEGF)), hematopoiesis, and inflammation (tool-like receptor 4 (TLR4)-mediated inflammation) [93,94]. Here, VEGFA is linked to metabolic dysfunction-associated steatotic liver disease.